Shed vs Medvi: GLP-1 Programs Compared

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Shed and Medvi are both telehealth-based GLP-1 prescription programs, but they differ significantly in program structure, medication options, pricing models, and clinical support depth. Both have grown substantially in the weight management market, each serving distinct patient populations seeking convenient access to GLP-1 therapies outside traditional medical settings.

Choosing between programs requires understanding not just cost and convenience, but also how your individual metabolic and genetic predispositions may align with available medication options. This article compares their models while introducing how biomarker and genetic context can support a more personalized conversation with your provider about which program structure fits your health profile.

Program Structure and Clinical Oversight Models

Shed operates as a membership-based telehealth platform emphasizing accessibility and direct-to-consumer convenience. Their model centers on matching patients with licensed providers for initial consultation, ongoing monitoring, and prescription management. Shed focuses on streamlined visits and flexible scheduling, positioning itself as a weight-loss-focused wellness service rather than a disease-management platform.

Medvi integrates a hybrid clinical model combining board-certified physicians with behavioral health coaching and nutritional guidance. Their approach frames GLP-1 therapy within a comprehensive wellness program that includes structured check-ins, progress tracking, and lifestyle support. Medvi's model appeals to patients seeking more intensive clinical oversight and multidisciplinary care coordination alongside medication management.

Medication Options and Dosing Protocols Compared

Both programs prescribe GLP-1 receptor agonists, but their formulary breadth and dosing flexibility differ. Understanding available medication variants—injectable semaglutide, oral semaglutide, tirzepatide, and dual-receptor compounds—is essential because individual response varies based on metabolic factors, genetic predispositions, and prior treatment history. This table outlines key differences in their typical medication availability and starting protocols.

Program Feature	Shed Typical Approach	Medvi Typical Approach	Clinical Relevance
Medication Range	Primarily semaglutide injectable and oral	Semaglutide and tirzepatide options	Tirzepatide (dual GLP-1/GIP agonist) offers alternative mechanism for nonresponders
Dosing Flexibility	Standard tiered dosing schedules	Individualized titration with provider consultation	Personalized dosing may align better with genetic metabolic variants
Starting Dose Protocol	Low-dose entry (0.25 mg semaglutide equivalent)	Provider-customized based on health history	Some patients benefit from ultramicrodose entry due to GLP1R genetic variants
Medication Switching	Program-dependent; may require new consultation	Integrated protocol for tirzepatide or alternative switching	Access to multiple compounds supports efficacy if first agent suboptimal

Pricing, Insurance, and Out-of-Pocket Cost Structures

Shed's pricing model emphasizes affordability through direct-pay options, typically ranging from $99–$299 monthly depending on medication strength and formulation. They do not primarily bill insurance, positioning themselves as a cash-pay alternative that bypasses insurance authorization delays. This appeals to patients with high deductibles or those seeking to avoid insurance documentation trails.

Medvi often attempts insurance billing when available, which can reduce patient out-of-pocket costs but requires longer authorization timelines and may involve copays ranging from $50–$200 monthly depending on plan coverage. Medvi's model assumes patients may have or seek insurance reimbursement, adding complexity but potentially lowering long-term costs for those with comprehensive coverage. Both programs charge consultation and monthly subscription or visit fees in addition to medication costs.

Clinical Evaluation and Patient Eligibility Frameworks

Shed typically conducts brief telehealth consultations (15–30 minutes) focused on BMI, comorbidities, and contraindication screening. Their eligibility criteria are streamlined for efficiency: BMI over 25, prior weight-loss attempts, and absence of personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. This rapid assessment prioritizes speed and accessibility over in-depth metabolic profiling.

Medvi requires more comprehensive initial evaluation including detailed medical history, vital signs, metabolic markers when appropriate, and sometimes laboratory testing depending on clinical judgment. Their provider-led screening emphasizes identifying contraindications, optimizing baseline health, and tailoring medication selection to patient-specific factors. This deeper assessment may identify whether genetic or biomarker considerations warrant specific medication choices or dosing strategies.

How Genetic and Metabolic Predispositions Inform Program Choice

Neither Shed nor Medvi currently integrate genetic testing into standard screening, yet individual differences in GLP-1 pathway biology significantly influence treatment outcomes. Genetic variants in GLP1R (glucose-dependent insulinotropic receptor sensitivity), GIPR (glucose-dependent insulinotropic peptide receptor function), and FTO (appetite regulation) can predict differential response to semaglutide versus tirzepatide or affect optimal dosing tolerability.

Patients with specific peptide pathway predispositions may benefit more from Medvi's provider-customized dosing and medication flexibility, or from programs offering genetic context before initiating therapy. Conversely, those seeking rapid access and cost efficiency may prioritize Shed's streamlined model alongside independent genetic testing to inform personal medication selection conversation. Understanding your individual peptide genetics can guide which program structure aligns best with your anticipated treatment response profile.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual predispositions in GLP-1 pathway variants—specifically GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—before selecting a treatment program. These insights can support a more informed conversation with your provider about whether semaglutide, tirzepatide, or dual-receptor compounds align with your metabolic biology. This information is intended to complement, not replace, clinical evaluation by a qualified healthcare provider.

The genetic test reveals predispositions in peptide pathway sensitivity, not exact medication response. Some patients with specific GLP1R genetic profiles, for example, may experience faster satiety signaling with standard-dose semaglutide, while others with different variants might benefit from tirzepatide's dual mechanism. PlexusDx compounded semaglutide and tirzepatide options—available from licensed 503A pharmacies at $149/mo monthly depending on formulation—can be prescribed through either traditional providers or participating telehealth partners based on your genetic and clinical context.

Whether you choose Shed's accessible, streamlined model or Medvi's comprehensive clinical approach, pairing your decision with genetic predisposition insights through Precision Peptide testing can enhance personalization. PlexusDx's test costs $99 as an add-on or $298 standalone and should be interpreted with a qualified healthcare provider to inform medication selection, dosing, and long-term treatment strategy aligned with your individual peptide biology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main clinical difference between Shed and Medvi's approaches to GLP-1 prescription?

Shed emphasizes rapid, cost-efficient telehealth access with streamlined provider consultations and cash-pay pricing. Medvi integrates comprehensive clinical oversight, behavioral coaching, and insurance billing attempts, appealing to patients seeking multidisciplinary support. Neither approach is universally superior; the choice depends on your...

Does either program cover insurance, and what are typical out-of-pocket costs?

Shed primarily operates on direct-pay models ($99–$299/month) without insurance billing. Medvi often attempts insurance claims, potentially reducing costs via copays ($50–$200/month) but requiring authorization delays. Both charge separate consultation and monthly service fees beyond medication costs. Check your specific plan and program for acc...

Can I use Shed or Medvi if I have prior health conditions like diabetes or thyroid concerns?

Both programs screen for contraindications including medullary thyroid cancer history and multiple endocrine neoplasia type 2. Medvi typically conducts more extensive health history review, which may be beneficial if you have complex comorbidities. Discuss your specific medical history with the program's provider before enrollment to confirm eli...

Does one program offer more medication options than the other?

Medvi typically provides access to both semaglutide and tirzepatide with individualized dosing flexibility. Shed primarily focuses on semaglutide formulations with standard tiered protocols. If you're interested in tirzepatide or require customized dosing due to side effects or prior treatment history, Medvi's broader formulary may offer more op...

How do genetic factors influence which GLP-1 program or medication might work best for me?

PlexusDx's Precision Peptide Genetic Test reveals predispositions in GLP1R, GIPR, FTO, and MC4R variants that may help contextualize individual semaglutide versus tirzepatide response and tolerability. This information can guide personalized medication selection within either program. Results should be reviewed with your provider to inform dosin...

Shed vs Medvi: Clinical Decision Framework for GLP-1 Treatment